# A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

> **NCT07756645** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 940 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ABBV-1480
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab- Paclitaxel

## Key facts

- **NCT ID:** NCT07756645
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-22
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 940 (ESTIMATED)
- **Last updated:** 2026-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756645, "A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07756645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*